human lambda light chain elisa kit (Bethyl)
Bethyl is a verified supplier 
93
Structured Review
Bethyl
human lambda light chain elisa kit
Human Lambda Light Chain Elisa Kit, supplied by Bethyl, used in various techniques. Bioz Stars score: 93/100, based on 52 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+lambda+light+chain+kit/Human+Lambda+ELISA+Kit/pm40043324-383-15-21
Average 93 stars, based on 52 article reviews
Human Lambda Light Chain Elisa Kit, supplied by Bethyl, used in various techniques. Bioz Stars score: 93/100, based on 52 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+lambda+light+chain+kit/Human+Lambda+ELISA+Kit/pm40043324-383-15-21
Average 93 stars, based on 52 article reviews
human lambda light chain elisa kit - by Bioz Stars,
2026-10
93/100 stars
Images
Related Articles
Generated:Article Title: Impact of fixed phosphorus position on activity of triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. Article Snippet: Geranylgeranyl diphosphate synthase (GGDPS) produces the 20-carbon isoprenoid species used in protein geranylgeranylation reactions.. Inhibition of GGDPS has emerged as a novel means of disrupting the activity of geranylgeranylated proteins in cancers such as myeloma and osteosarcoma.. We have focused on developing a series of isoprenoid triazole bisphosphonate-based GGDPS inhibitors, demonstrating a complex structure–activity relationship (SAR), not only at the enzymatic level, but also at the cellular and whole organism levels. Article Title: Incorporation of an alpha-hydroxy substituent modulates activity of triazole bisphosphonate-based geranylgeranyl diphosphate synthase inhibitors. Article Snippet: Geranylgeranyl diphosphate synthase (GGDPS), the enzyme responsible for producing the isoprenoid substrate used in protein geranylgeranylation reactions, represents a novel therapeutic target in cancer, including malignancies such as multiple myeloma and osteosarcoma.. Our work has focused on the development of a series of isoprenoid triazole bisphosphonate-based GGDPS inhibitors.. Previous work has revealed that our lead GGDPS inhibitors do achieve substantial systemic distribution, in contrast to clinically used nitrogenous bisphosphonates which accumulate primarily in the bone. Western Blot:Article Title: Impact of fixed phosphorus position on activity of triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. Article Snippet: Geranylgeranyl diphosphate synthase (GGDPS) produces the 20-carbon isoprenoid species used in protein geranylgeranylation reactions.. Inhibition of GGDPS has emerged as a novel means of disrupting the activity of geranylgeranylated proteins in cancers such as myeloma and osteosarcoma.. We have focused on developing a series of isoprenoid triazole bisphosphonate-based GGDPS inhibitors, demonstrating a complex structure–activity relationship (SAR), not only at the enzymatic level, but also at the cellular and whole organism levels. Article Title: Incorporation of an alpha-hydroxy substituent modulates activity of triazole bisphosphonate-based geranylgeranyl diphosphate synthase inhibitors. Article Snippet: Geranylgeranyl diphosphate synthase (GGDPS), the enzyme responsible for producing the isoprenoid substrate used in protein geranylgeranylation reactions, represents a novel therapeutic target in cancer, including malignancies such as multiple myeloma and osteosarcoma.. Our work has focused on the development of a series of isoprenoid triazole bisphosphonate-based GGDPS inhibitors.. Previous work has revealed that our lead GGDPS inhibitors do achieve substantial systemic distribution, in contrast to clinically used nitrogenous bisphosphonates which accumulate primarily in the bone. Enzyme-linked Immunosorbent Assay:Article Title: Impact of fixed phosphorus position on activity of triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. Article Snippet: Geranylgeranyl diphosphate synthase (GGDPS) produces the 20-carbon isoprenoid species used in protein geranylgeranylation reactions.. Inhibition of GGDPS has emerged as a novel means of disrupting the activity of geranylgeranylated proteins in cancers such as myeloma and osteosarcoma.. We have focused on developing a series of isoprenoid triazole bisphosphonate-based GGDPS inhibitors, demonstrating a complex structure–activity relationship (SAR), not only at the enzymatic level, but also at the cellular and whole organism levels. Article Title: Super enhancer acquisition drives expression of oncogenic PPP1R15B that regulates protein homeostasis in multiple myeloma. Article Snippet: .. The supernatants were collected for analysis of the secreted human immunoglobulin λ or κ light chains by enzyme-linked immunosorbent assay (ELISA), according to the manufacturer’s instructions ( Article Title: Incorporation of an alpha-hydroxy substituent modulates activity of triazole bisphosphonate-based geranylgeranyl diphosphate synthase inhibitors. Article Snippet: Geranylgeranyl diphosphate synthase (GGDPS), the enzyme responsible for producing the isoprenoid substrate used in protein geranylgeranylation reactions, represents a novel therapeutic target in cancer, including malignancies such as multiple myeloma and osteosarcoma.. Our work has focused on the development of a series of isoprenoid triazole bisphosphonate-based GGDPS inhibitors.. Previous work has revealed that our lead GGDPS inhibitors do achieve substantial systemic distribution, in contrast to clinically used nitrogenous bisphosphonates which accumulate primarily in the bone. Article Title: The oligosaccharyltransferase complex is an essential component of multiple myeloma plasma cells Article Snippet: MYC and 523 GADPH mRNAs were detected by real-time PCR (QuantStudio 3, Applied Biosystems, USA). .. 524 525 Human lambda light chain ELISA 526 The Nunc 96-well plates (Thermo Scientific) were coated with goat anti-human lambda chain 527 antibody (20 μg/mL) (Southern Biotechnology, #2070-01) in coating buffer ( Article Title: The oligosaccharyltransferase complex is an essential component of multiple myeloma plasma cells Article Snippet: MYC and GADPH mRNAs were detected by real-time PCR (QuantStudio 3, Applied Biosystems, USA). .. The Nunc 96-well plates (Thermo Scientific) were coated with goat anti-human lambda chain antibody (20 μg/mL) (Southern Biotechnology, #2070-01) in coating buffer ( Article Title: EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction Article Snippet: .. Biomarker Discovery:Article Title: Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells Article Snippet: .. The levels of the tumor biomarker IgG2B (Invitrogen; Cat#88-50430-88), a paraprotein produced by 5TGM1 cells, or Article Title: Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells. Article Snippet: Gene expression was quantified by quantitative real-time PCR (qPCR) using TaqMan assays from Applied Biosystems (Foster City, CA, USA), according to the manufacturer's instructions. .. The levels of the tumor biomarker IgG2B (Invitrogen; Cat#88-50430-88), a paraprotein produced by 5TGM1 cells, or Produced:Article Title: Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells Article Snippet: .. The levels of the tumor biomarker IgG2B (Invitrogen; Cat#88-50430-88), a paraprotein produced by 5TGM1 cells, or Article Title: Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells. Article Snippet: Gene expression was quantified by quantitative real-time PCR (qPCR) using TaqMan assays from Applied Biosystems (Foster City, CA, USA), according to the manufacturer's instructions. .. The levels of the tumor biomarker IgG2B (Invitrogen; Cat#88-50430-88), a paraprotein produced by 5TGM1 cells, or In Vivo:Article Title: Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells Article Snippet: .. The levels of the tumor biomarker IgG2B (Invitrogen; Cat#88-50430-88), a paraprotein produced by 5TGM1 cells, or Article Title: Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells. Article Snippet: Gene expression was quantified by quantitative real-time PCR (qPCR) using TaqMan assays from Applied Biosystems (Foster City, CA, USA), according to the manufacturer's instructions. .. The levels of the tumor biomarker IgG2B (Invitrogen; Cat#88-50430-88), a paraprotein produced by 5TGM1 cells, or Ex Vivo:Article Title: Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells Article Snippet: .. The levels of the tumor biomarker IgG2B (Invitrogen; Cat#88-50430-88), a paraprotein produced by 5TGM1 cells, or Article Title: Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells. Article Snippet: Gene expression was quantified by quantitative real-time PCR (qPCR) using TaqMan assays from Applied Biosystems (Foster City, CA, USA), according to the manufacturer's instructions. .. The levels of the tumor biomarker IgG2B (Invitrogen; Cat#88-50430-88), a paraprotein produced by 5TGM1 cells, or Incubation:Article Title: The oligosaccharyltransferase complex is an essential component of multiple myeloma plasma cells Article Snippet: MYC and 523 GADPH mRNAs were detected by real-time PCR (QuantStudio 3, Applied Biosystems, USA). .. 524 525 Human lambda light chain ELISA 526 The Nunc 96-well plates (Thermo Scientific) were coated with goat anti-human lambda chain 527 antibody (20 μg/mL) (Southern Biotechnology, #2070-01) in coating buffer ( Article Title: The oligosaccharyltransferase complex is an essential component of multiple myeloma plasma cells Article Snippet: MYC and GADPH mRNAs were detected by real-time PCR (QuantStudio 3, Applied Biosystems, USA). .. The Nunc 96-well plates (Thermo Scientific) were coated with goat anti-human lambda chain antibody (20 μg/mL) (Southern Biotechnology, #2070-01) in coating buffer ( |
